Kaiser Permanente's Genetic Database Is Boon to Medical Research
By Emily Anthes,
Bloomberg Businessweek
| 09. 25. 2014
Untitled Document
Over the past decade, Kaiser Permanente has spent more than $4 billion building the world’s largest private-sector collection of electronic health-care records. The data have become the cornerstone of a new scientific resource: a biobank that links the health records of more than 210,000 Kaiser members with samples of their DNA. The Oakland (Calif.)-based health network has teamed up with the University of California at San Francisco so scientists can use the collection to search for the genetic roots of diseases including glaucoma and prostate cancer.
Kaiser has 9.5 million enrollees in eight states and the District of Columbia, and members can see a wide variety of medical specialists without leaving the network. Every visit, lab test, prescription, and procedure is logged into a member’s electronic health record. This gives Kaiser an edge over other genomics projects, which besides collecting DNA samples must go through the expense and trouble of amassing information on subjects’ medical history. Last year biologist Craig Venter founded Human Longevity, with plans to sequence the genomes of as many as 100,000 people annually, and this summer,...
Related Articles
By Alex Aylward, Daniel J. Fairbanks, Maria Kiladi, and Gregory Radick , Heredity | 04.20.2026
Genetics and eugenics co-evolved at the beginning of the twentieth century and remained associated through the 1940s and beyond. Early geneticists were far from unanimous in their views on eugenics; some avidly supported the movement, whereas others openly opposed it...
By Staff, GMWatch | 03.28.2026
Following a recent podcast interview we were asked whether there is any solid scientific research looking at how gene expression or molecular composition in genetically modified (GM) plants differs from conventionally bred plants. As this is an interesting and important...
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
By Ryan Cross, Endpoints News | 03.24.2026
Cathy Tie has an audacity more typical of a tech startup founder than a biotech executive. She dropped out of college to start a genetic screening company and later founded a telemedicine startup. The 29-year-old has been on two Forbes...